An interventional study of Sputum sample and Venepuncture in COPD, sponsored by Northumbria Healthcare NHS Foundation Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 35 Years and older. Per ClinicalTrials.gov, last updated 2026-04-23.
Sponsored by Northumbria Healthcare NHS Foundation Trust · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 621 studies in Pulmonary Disease, Chronic Obstructive with a site in United Kingdom — 60 open to participants now, 76 under way, 10 of them phase 3. Pulmonary Disease, Chronic Obstructive · United Kingdom.
Among the 621 studies in Pulmonary Disease, Chronic Obstructive with a site in United Kingdom, this one is the 209th largest by planned enrollment of the 466 interventional ones that give a count, is one of 17 that started in 2026, is one of 122 with no phase, reaches primary completion later than 67 of the 75 other live ones, and was the 606th registered.
5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →60 of the 621 studies in Pulmonary Disease, Chronic Obstructive with a site in United Kingdom are open now. Recruiting first, the newest first:
AeroRx Therapeutics Inc. · Sites in United Kingdom
Ages 40–75
Richmond Research Institute · Sites in United Kingdom
Ages 18+
GlaxoSmithKline · Sites in United Kingdom, United States
Ages 40–80
Hoffmann-La Roche · Sites in United Kingdom
Ages 18–80 · Healthy volunteers
Liverpool Heart and Chest Hospital NHS Foundation Trust · Sites in United Kingdom
Ages 18–110
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.
This study: 35 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
621 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 102 · Phase 2 109 · Phase 3 100 · Phase 4 50
First in 2000; this study’s year is marked. 17 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 96 is above the median of 62 across 3,847 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 80 across the 466 interventional studies, 104 across the 155 observational. Of the 476 that completed or were terminated, 149 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
342 of 621 have an industry lead sponsor. The 10 most frequent:
Northumbria Healthcare NHS Foundation Trust is the lead sponsor of 16 studies on the registry; 4 are open to participants now.
Northumbria Healthcare NHS Foundation Trust has 4 studies filed under Pulmonary Disease, Chronic Obstructive — fewer than ten, so there is no comparison to draw.
26 of the studies in Pulmonary Disease, Chronic Obstructive with a site in United Kingdom that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05878769Phase 3Hoffmann-La RocheA Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) | 2027-06-30 |
| NCT06712563AstraZenecaPooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting | 2026-12-14 |
| NCT06154837GlaxoSmithKlineA Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease | 2026-12-16 |
| NCT07102823Medical University of GrazClinical Registry for the Characterization of the 'Pulmonary Vascular Phenotype' in Patients With Chronic Obstructive Pulmonary Disease | 2026-12-30 |
| NCT04236726Guy's and St Thomas' NHS Foundation TrustInvestigating Health Related Quality of Life in Patients With Chronic Respiratory Failure | 2026-12-31 |
Add all 26 to your calendar (.ics) → With an account.
Among the 621 studies in Pulmonary Disease, Chronic Obstructive with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Background:
Chronic obstructive pulmonary disease (COPD) is a serious lung condition and the third leading cause of death worldwide. People with COPD have sudden and distressing flare-ups (exacerbations). These can be triggered by infections or occur without a clear cause. Flare-ups often lead to hospital admission, can cause a lasting health decline, increase the risk of dying and are strongly liked to lower income.
Sometimes, people are wrongly diagnosed with COPD, when they have a different health issue. Other diseases (like heart conditions) are common in people with COPD, and share similar symptoms. These have often not been diagnosed and worsening of these conditions can look like a flare-up of COPD, leading to incorrect treatment. Additionally, many people with COPD have not been offered appropriate treatments that would reduce their flare-up frequency.
COPD flare-ups are treated with steroid tablets (prednisolone), and sometimes antibiotics. Frequent use of prednisolone causes side effects such as weight gain, bone thinning (osteoporosis) and diabetes. Reducing how often people with COPD have flare-ups can reduce these side effects.
The investigators aim to reduce COPD flare-ups and prevent harm from prednisolone by improving the treatment of COPD, while also checking for other health conditions.
The goal:
In people with COPD, who take prednisolone for flare-ups (three of more times a year), the investigators want to see if a thorough assessment (that focuses on the treatment of COPD and diagnosis of other common health problems), reduces the number of flare-ups that need prednisolone over the next year.
Design:
Participants will attend a half-day hospital visit for a thorough check-up (a mini-MOT). The assessment includes a review by a doctor, questionnaires, blood tests, breathing tests, a scan of the chest (CT), and investigations on the heart. The investigators will make sure participants receive the correct treatment for their COPD.
The assessment will focus on three areas: lung health, identifying and treating important health issues outside of the lungs (that may be contributing or causing symptoms similar to COPD) and supporting changes in behaviours that can improve lung health. These factors (whether in the lungs, body or related to lifestyle) are known as treatable traits.
The investigators will also review participants prednisolone use and check for health problems that may have been caused by it. At the end of the assessment participants will be given a personalised treatment plan.
Participants will be followed up for 12 months, at 3 month intervals. During this time they will collect information on the number of emergency hospital visits, serious heart-related events, steroid tablets taken for COPD flare-ups and any deaths. They will ask participants to complete short questionnaires about their health and wellbeing.
Who provided advise on this study :
Preventing COPD flare-ups is a top priority, identified by The James Lind Alliance (a national research priority setting partnership). This study was reviewed by the Northumbria Lung Research Patient Advisory Group (people living with COPD). They felt the study was well-designed and likely to make a meaningful difference. People with experience in research and COPD also gave feedback, and changes were made, such as reducing travel requirements, based on their views. The research team has successfully completed studies that have led to real improvement in COPD care, and are committed to ensuring this study has a similar positive impact.
Sharing results:
At the end of the study results will be shared with the public, study participants, healthcare workers, commissioners and guideline advisory groups. The findings will be shared on online platforms, present them at national/international conferences, and published in medical journals. The aim is to ensure findings improve clinical practice, policies and guidelines.
Background:
Chronic obstructive pulmonary disease (COPD) is a serious lung condition and the third most common cause of death worldwide. In England, COPD causes 121,129 hospital stays and 20,000 deaths each year. Despite how common and serious it is, only 2% of public research funding targets lung diseases like COPD.
People with COPD have sudden and distressing flare-ups (exacerbations). These can be triggered by infections or occur without a clear cause. Exacerbations are serious, they often lead to hospital admission, can cause a lasting health decline, increase the risk of dying and are strongly liked to lower income.
Frequent exacerbators is a term used to describe people who experience 2 or more COPD exacerbations each year, and super-exacerbators have 3 or more exacerbations each year. COPD flare-ups are treated with steroid tablets (prednisolone) and sometimes antibiotics. Steroid tablets help recovery but frequent use causes side effects such as weight gain, bone thinning (osteoporosis) and diabetes. People with COPD receive steroids very frequently; a third of all UK steroid prescriptions are for people with COPD, and this number is increasing.
Sometimes, people are wrongly diagnosed with COPD, when they have a different health issue. Other diseases (like heart conditions) are common in people with COPD, and share similar symptoms. These have often not been diagnosed and worsening of these conditions can look like a flare-up of COPD, leading to incorrect treatment. Additionally, many people with COPD have not been offered appropriate treatments that would reduce their flare-up frequency.
Treatable traits are health-related factors (linked to the lungs, the body and lifestyle choices) that, when identified and managed, can help improve a person's health. Unfortunately many people who are at risk of frequent COPD flare ups are not getting the care they need. According to a 2024 survey by Asthma and Lung UK only 9% of people with COPD are receiving all the key parts of recommended care.
The primary aim of the study is to find out if a thorough health assessment, focused on improving participants COPD treatment and identifying other health problems (treatable traits, conditions caused by prednisolone and other common health conditions) will reduce the number of COPD flare-ups individuals have over the next year.
STOPmyCOPD focuses on a group of people who have very frequent COPD exacerbations. They are often from disadvantaged backgrounds, rely heavily on healthcare services, and experience worse health outcomes. There is a need to improve diagnoses and treatment in these patients.
What is STOPmyCOPD:
STOPmyCOPD is a research study looking at people with COPD, who take prednisolone (steroids) for flare-ups of their condition, three of more times a year. The investigators want to see if a thorough assessment (that focuses on the treatment of COPD and diagnosis of other common health conditions), reduces the number of flare-ups that need prednisolone over the next year.
Secondary research questions:
Who has been involved:
STOPmyCOPD has been designed for patients and the wider NHS. It supports the goals of the North East and North Cumbria Integrate Care Board and directly addresses the top research priorities of the James Lind Alliance for managing COPD flare-ups (exacerbations).
Seven people with confirmed COPD and a strong interest in research reviewed the study. They looked at how relevant it was, how practical it was and what challenges might occur. They felt STOPmyCOPD tackled an important issue and found the study design clear. Importantly they felt the number of clinic visits and tests were reasonable. One person raised a concern about travel time, so the assessment was amended to a half-day visit, reducing travel burden.
The Northumbria Lung Research Patient Advisory Group (PAG), a group of people with COPD also gave feedback. They felt a study of this type was urgently needed. They highlighted that the number of research trials for people with COPD is limited and that COPD research is underfunded. The PAG highlighted the importance of using easy to understand language in documents for patients. The group recommended having regular meetings every six months to stay involved in the study, and this has been built into the design.
The study design was developed with the help of Dr Nan Lin (Senior Lecturer in Biostatistics , Population Health Sciences Institute, Newcastle University). He is an expert in this type of research. It has additionally been reviewed by two independent experts in COPD and a Teaching and Research Fellowship committee reviewed the project as part of a Teaching and Research Fellowship. The study was reviewed by AstraZeneca as part of their externally sponsored scientific research (ESR). This underwent review by the Global Reviewing Committee and was endorsed to be scientifically and strategically valid. Consistent and extremely positive feedback was received from all reviewers.
The the host organisation has reviewed and fully endorsed the project.
Design:
The study uses a design where each person is compared to themselves over time (stepped wedge cluster randomisation study). This means the investigators will look at how often each participant had COPD flare-ups before and an intervention, rather than comparing them to other people. Adjustments for external factors (such as the prevalence of flu in the community at the time) will be made to ensure these factors do not affect the results.
The study requires 96 participants, with recruitment scheduled over 24 months. This value includes a margin of error in case some people leave the study early.
Recruitment:
Adults aged 35 and over, who have COPD and have taken three or more courses of prednisolone (in the past 12-months) to treat COPD flare-ups will be invited to patricipate. At the time of entering the study participants must not have had a flare up in the last four weeks.
People will not be able to take part if they take steroids tablets (prednisolone) every day for another health condition, have had a lung transplant, use a type of breathing support called NIV (non-invasive ventilation), are housebound or have a serious illness that means they spend most time at home or are unlikely to live beyond 12 months.
Participants will be identified through a number of different channels across the North East and North Cumbria Region:
A member of the research team will contact eligible participants by telephone, letter or in person, once they have confirmed they are willing to be contacted. They will provide a patient information sheet, which participants can read themselves or have read aloud to them. Ample time will be given to review the information, ask questions and consider participation. Any questions will be answered by a trained member of the research team.
Participants will be reimbursed for travel and will also receive a £100 voucher at the end of the study as a thankyou.
Method:
The study involves a hospital visit, a follow up appointment, and four telephone calls. The first appointment is a hospital visit in which participants undergo the detailed health check. Following this there is one review appointment followed by four short telephone calls over the next year.
Before the Health Assessment Before the health assessment basic information from participants electronic health record will be collected. This will include demographics, past medical conditions and current medications.
The Detailed Health Assessment
The hospital visit will take around half a day. During this visit the study team will:
d) Support behaviour changes that can improve lung health. e) Provide targeted education.
Participants will be seen by a doctor and asked to complete questionnaires about their health and quality of life. They will undergo the following investigations:
Depending on these test results some participants may require further investigations These could include a more detailed scan of the heart (CT coronary angiogram), a bone scan (DEXA), a sleep study and additional blood tests (arterial blood gas). These tests will not be required in all participants and may be arranged to happen at a later date.
At the end of the assessment the study team will make sure participants are receiving the correct treatment for their COPD. If any new health conditions (comorbidities) are found, treatment (for example new medication) will be started and optimisation by the study team/or GP. Any treatment offered will follow national NHS guidance and be part of standard care. Participants GP will be kept fully informed of any new diagnoses or treatments.
Follow Up:
Eight weeks after the health assessment the study team will contact participants to discuss their results and any new diagnoses. The team will review whether any new treatments have been started and whether medication is being taken as prescribed.
Participants will then be followed up every 3 months for 12 months with short telephone assessments. During these encounters participants will complete questionnaires about their health and wellbeing. The study team will also collect information about them from their electronic health record, such as the number of emergency hospital visits, serious heart-related events, prednisolone courses taken for COPD flare-ups and deaths.
Timeline:
Recruitment is scheduled for March 2026, with results expected in 2029. There is a planned 24-month recruitment period, allowed the last participant 12 months to complete follow-up.
Sharing results:
This study targets a group of people who face significant health challenges and often have poor health outcomes. At the end of the study results will be shared with the public, study participants, healthcare workers, commissioners and guideline advisory groups. The findings will be shared on online platforms, present them at national/international conferences, and published in medical journals. To ensure results reach policymakers, the investigators will also engage with the British Thoracic Society COPD Specialist Advisory Group, NICE, and Asthma and Lung UK. The aim is to ensure findings improve clinical practice, policies and guidelines.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Structured Health Assessment 1. Confirm (or exclude) the COPD diagnosis and measure study outcomes 2. Identify and treat pulmonary, extra-pulmonary and modifiable behaviour traits 3. Perform a comprehensive multi-morbidity assessment 4. Deliver targeted educational interventions
Diagnostic Test: Sputum sample · Diagnostic Test: Venepuncture · Diagnostic Test: Lung function test · Diagnostic Test: Medical history and physical examination · Diagnostic Test: Blood pressure · Diagnostic Test: BMI · Radiation: HRCT of chest · Diagnostic Test: ECG · Diagnostic Test: Echo · Diagnostic Test: Subject Questionnaires · Diagnostic Test: Research Questionnaires · Biological: Influenza Vaccines · Biological: Pneumococcal Vaccine · Biological: RSV F vaccine (0.5mL injection) · Diagnostic Test: Oxygen saturation (+/- ABG) · Radiation: DXA · Behavioral: Education
Sputum sample
FBC, Total IgE, Corrected Calcium, Vitamin D, Liver function test, Early morning cortisol, HbA1C, NT pro BNP, Lipid panel, U\&E
Spirometry, FENO +/- Gas transfer, body plethysmography
Medical history and physical examination
Blood pressure
Weight and height Waste and hip circumference
HRCT of chest (Strat X protocol) with coronary artery caclium score
Electrocardiogram
Echocardiogram
Clinical questionnaires: ESS, FRAX score, QRISK4,
Research questionnaires: eMRCD, SQRQ-C, EQ-5D-5L, HADS-A, HADS-D, Seven step inhaler technique, PIH scale
For those eligible under usual standard of care
For those eligible under usual standard of care
For those eligible under usual standard of care
Resting oxygen saturation on room air (+/- ABG)
Participants with a high or intermediate FRAX® risk score, or those aged \>50 years with a history of fragility fractures, will be offered a dual-energy x-ray absorptiometry scan (DXA)
Education on Inhaler Technique, Medication Adherence, Tobacco \& Substance Abuse, Physical Activity, and COPD Self Management
Cumulative dose of oral prednisolone over 12-months*. * excluding short courses of prednisolone prescribed for conditions not related to airway exacerbations (e.g. anaphylaxis, inflammatory bowel disease, cutaneous skin disorders).
Time frame: 12 months (commencing 8 weeks after structured assessment complete). Measured at 5, 8, 11 and 14 months from enrolment.
Proportion of participants with confirmed COPD (based on spirometry and clinical assessment).
Time frame: From enrolment to end of structured assessment (week 1)
Distribution of COPD by severity, endotype and phenotype.
Time frame: From enrolment to end of structured assessment (week 1)
Proportion of participants receiving new or adjusted COPD-specific treatments.
Time frame: From enrolment to review of investigation outcomes and adherence (week 8)
Proportion of participants with each comorbidity, stratified by whether the condition was previously recognised or newly identified.
Time frame: From enrolment to review of investigation outcomes and adherence (week 8)
Number of new treatments initiated (per participant), both overall and by specific therapy (class/ type), started as result of the multidimensional assessment
Time frame: Last subject, 8 week review
Total cumulative dose of oral prednisolone (per year) for the past 10 years (or since COPD diagnosis if more resent).
The cumulative dose of oral prednisolone (per year) for the past 10 years will be recorded, except for participants whose diagnosis is less than 10 years old and who therefore have not had the opportunity to receive prednisolone for the full 10-year period.
Time frame: From enrolment to end of structured assessment (week 1)
Number of oral prednisolone courses (per year) over the past 10 years (or since COPD diagnosis if more resent).
The number of prescribed course of oral prednisolone (per year) for the past 10 years will be recorded, except for participants whose diagnosis is less than 10 years old and who therefore have not had the opportunity to receive prednisolone for the full 10-year period.
Time frame: From enrolment to end of structured assessment (week 1)
Covariates independently associated with cumulative corticosteroid dose.
The dependent variable is total cumulative corticosteroid dose (measured in mg prednisolone over 12 months or equivalent if an alternative corticosteroid is administered). Multiple regression modelling will be used to identify demographic, physiological, clinical and psychological covariates independently associated with cumulative corticosteroid exposure. Effect estimates will be reported as regression coefficients with 95% confidence intervals. Key candidate varibles are lised below: * Demographic:Age, Sex * Physiological:BMI (weight and height combined to BMI in kg/m\^2), FEV1, FeNO, Blood eosinophils, Total IgE * Clinical:Change in primary diagnosis, phenotype, cumulative corticosteroid use 12 months prior to study entry, inpatient days over 12 months prior to study entry, maintenance inhaled therapy, azithromycin, biologic therapy, LTOT, comorbidities (previously recognised and new), eMRCD, pulmonary rehab within 12 months of study entry (prior or prospectively) * HADS Score, SGRQ.
Time frame: From visit 2: 8 weeks to end of study (14 months)
Mortality: all cause and respiratory.
Time frame: 14 months from enrolment. Measured at 5, 8, 11 and 14 months.
Non fatal and fatal major adverse cardiovascular events
Time frame: 14 months from enrolment. Measured at 5, 8, 11 and 14 months
Time to first cardiopulmonary event.
Time frame: 14 months from enrolment. Measured at 5, 8, 11 and 14 months
Time to death (all cause and respiratory).
Time frame: 14 months from enrolment. Measured at 5, 8, 11 and 14 months
12. Mean change in St George's Respiratory Questionnaire- COPD
Sum of maximum possible weights for each component and Total: Symptoms: 566.2 Activity: 982.9 Impacts: 1652.8 Total (sum of maximum for all three components) 3201.9 (Note: these are the maximum possible weights that could be obtained for the worst possible state of the patient).
Time frame: 14 months from enrolment. Measured at week 1, 5 months, 8 months, 11 months and 14 months.
12. Mean change in quality of life (EQ-5D-5L)
5 health states scored out of 5. Level 1: indicating no problem, Level 5: indicating unable to/extreme problems.
Time frame: 14 months from enrolment. Measured at week 1, 5 months, 8 months, 11 months and 14 months.
12. Mean change in quality of life (EQ VAS)
EQ VAS- total score 100. 100 is the best health, 0 the worst health.
Time frame: 14 months from enrolment. Measured at week 1, 5 months, 8 months, 11 months and 14 months.
Mean change in anxiety and depression (Hospital Anxiety and Depression Scale)
HADS A -21 points HADS D- 21 points 0-7 = Normal 8-10 = Borderline abnormal (borderline case) 11-21 = Abnormal (case)
Time frame: 14 months from enrolment. Measured at week 1 and 14 months.
Change in patient activation (Partners in health scale)
12 areas scored out of 9 (zero being the lowest response, reflecting low self-management capacity, and eight being the highest, reflecting good self-management capacity).
Time frame: 14 months from enrolment. Measured at week 1 and 14 months.
Number of moderate and severe exacerbations
Time frame: 14 months from enrolment. Measured at 5, 8, 11 and 14 months
Number of severe ECOPD (unplanned hospital admission) per annum.
Time frame: 14 months from enrolment. Measured at 5, 8, 11 and 14 months
Number of Emergency department visits per annum: all-cause and respiratory.
Time frame: 14 months from enrolment. Measured at 5, 8, 11 and 14 months
Inpatient hospital bed days per annum: all cause and respiratory.
Time frame: 14 months from enrolment. Measured at 5, 8, 11 and 14 months
Non fatal major adverse cardiovascular events per annum (nonfatal stroke, nonfatal myocardial infarction).
Time frame: 14 months from enrolment. Measured at 5, 8, 11 and 14 months
Total cumulative dose of oral prednisolone per year over the past 10 years (or since COPD diagnosis if more resent).
Time frame: From enrolment to end of structured assessment (week 1)
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Mar 2029, 35 months after the start.
Of 1,099 non-industry interventional studies with no phase under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 35 months is above that.
Counting every sponsor, half of 1,187 studies reached it within 22 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →
Northumbria Healthcare NHS Foundation Trust